

FOR IMMEDIATE RELEASE

Contact:

Johna Carufel

Business Services Manager

9001 Wesleyan Road, Suite 200

Indianapolis, IN 46268

Ph. (317) 569-9500 x 117

Fax (317) 569-9520

Cell (317) 201-8711

www.ansongroup.com

jcarufel@ansongroup.com

THE ANSON GROUP ANNOUNCES SCOTT THIEL, MBA, ASCP, RAC, JOINS THE FIRM AS A SENIOR REGULATORY CONSULTANT

(INDIANAPOLIS, INDIANA) August 16, 2011 The Anson Group is pleased to announce that Scott Thiel has joined the firm as a senior regulatory consultant serving both the medical device and connected health needs of Anson's growing client portfolio.

Mr. Thiel comes to Anson from Roche Diagnostics where he has served the past 22 years, most recently as the Global Regulatory Affairs Program Manager for the Diabetes Care Division. He brings extensive medical device industry knowledge and regulatory experience to Anson in the areas of diagnostics, diabetes care, product research and development, and post market and labeling requirements, as well as being highly involved and active in the development of regulatory strategy and advocacy for interoperable and networked medical device technologies. He also brings a global regulatory perspective and understanding of the different requirements of the US, Canada, EU, and other regulatory authorities, as well as the harmonization efforts to standardize requirements across the different agencies. Mr. Thiel has experience working with important industry standards such as ISO 14971, 13485, and IEC 62366, as well as regulatory requirements of FDA 21 CFR 820 Quality Systems and the European Union's Medical Device Directive (MDD), the In Vitro Diagnostics Directive (IVDD), and CE Marking.

Mr. Thiel has been active in a number of medical device industry trade associations and advocacy groups including Advamed, AAMI, CLSI, and the Combination Products Coalition for drugs and medical devices. Mr. Thiel has also been equally active in the future development of interconnected and interoperable medical technologies, serving as the Regulatory Working Group Chair for the Continua Alliance and as a member of the mHealth Regulatory Coalition focused on the unique challenges of mobile networks that include regulated medical technology.

“We are very excited to have Scott bring his unique skills and expertise to the Anson Group”, states Anson’s CEO Colleen Hittle. “Nearly every Anson client finds themselves faced with the increased reliance on complex diagnostic technology paired with therapeutic treatments and the still unfamiliar territory of connecting regulated medical technologies to mobile cellular networks or to enterprise networks inside a healthcare provider facility. Scott will be a tremendous asset to engage with our clients who must find a way to commercialize their products today in a way that meets the existing regulatory requirements. No one understands what this will entail better than Scott.”

About Anson Group

The Anson Group is a woman-owned independent regulatory consulting organization headquartered in Indianapolis, IN. Since 1996, the Anson Group has provided tailored, client-focused regulatory compliance solutions for medical device, pharmaceutical, biologics, combination product and most recently, connected health clients. Looking at issues in the context of our clients’ resources and culture, our team of industry experts identifies available regulatory options and helps select the best pathway for overall client success.

